|
MRI News Service:
'In Phase' p3 |
|
|
|
 |
 | | | '''Baltimore, MD - The publication of a negative phase 2 trial of an investigational compound for reperfusion injury has prompted discussion about how best to assess the efficacy of agents for this indication in the future [1]. The FX06 in Ischemia and ...' | | Friday, 30 January 2009 by www.theheart.org |
|
|
|
| | | '''Physicists at Los Alamos National Laboratory, along with colleagues at institutions in Switzerland and Canada, have observed, for the first time in a single exotic phase, a situation where magnetism and superconductivity are necessary for each other's ...' | | | Thursday, 28 August 2008 by www.nanotech-now.com | |
|
|
|
| | | '''SCI Engineered Materials Inc. has clinched a contract with the Energy Department to help launch the second phase of a Small Business Innovation Research project. The Columbus-based maker of specialty ceramics and metals was awarded a two-year ...' | | | Tuesday, 19 August 2008 by columbus.bizjournals.com | |
|
|
|
| | | '''A NEW technique for creating images of the living brain, developed by Australian scientists, can spot early signs of Parkinson's and Alzheimer's long before symptoms appear. Researchers from the Howard Florey Institute in Melbourne say their ...' | | | Monday, 16 June 2008 by www.theage.com.au | |
|
|
|
| | | '''WALTHAM, Mass., March 26 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company has initiated a Phase 3 clinical trial to evaluate the use of RG1068, synthetic human secretin, to improve the assessment of ...' | | | Wednesday, 26 March 2008 by www.prnewswire.com | |
|
|
|
| | | '''Researchers at the US Department of Energy’s Lawrence Berkeley National Laboratory and the University of California, Berkeley, have successfully studied gas-phase reactions on the microscale using magnetic resonance imaging (MRI). The application ...' | | | Thursday, 31 January 2008 by www.theengineer.co.uk | |
|
|
|
| | | '''CHICAGO and SUNNYVALE, Calif., June 3 /PRNewswire-FirstCall/ --
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced final results from an
open-label multi-center Phase 2 clinical trial, which indicated that
Xcytrin(R) (motexafin gadolinium) ...' | | | Sunday, 3 June 2007 by www.prnewswire.com | |
|
|
|
| | | '''SUNNYVALE, Calif., Nov 09, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the presentation of preliminary results of an open-label multi-center Phase 2 clinical trial, which suggest that ...' | | | Thursday, 9 November 2006 by ir.pharmacyclics.com | |
|
|
|
| | | '''SUNNYVALE, Calif., Dec 19, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced top-line results from its pivotal Phase 3 clinical study of Xcytrin(R) (motexafin gadolinium) Injection, for the ...' | | | Monday, 19 December 2005 by www.prnewswire.com | |
|
|
|
| | | '''CAMBRIDGE, Mass., Aug. 11 /PRNewswire-FirstCall/ -- Advanced Magnetics, Inc. today announced that after a recent meeting with the U.S. Food and Drug Administration (FDA) to evaluate its Phase III development program for ferumoxytol in IV iron ...' | | | Thursday, 11 August 2005 by www.biospace.com | |
|
|
|
|
|
|
|
|
| Result Pages |
|
|
|
|
|
No matter how rich you become, how famous or powerful, when you die the
size of your funeral will still pretty much depend on the weather.
-
Michael Pritchard |
|
|
News
top
